Allscripts Healthcare Solutions (NASDAQ:MDRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at Maxim Group in a research report issued on Tuesday, January 9th. They currently have a $20.00 price target on the software maker’s stock. Maxim Group’s price target suggests a potential upside of 31.23% from the company’s current price.
The analysts wrote, “MDRX announced the acquisition of Practice Fusion, a provider of cloud- based electronic health record (EHR) platforms, for $100M in cash. The acquisition is expected to close in 1Q18. We believe Practice Fusion was sold at 1.0x-2.0x revenue, implying a $50M- $100M revenue run rate. It is expected to be marginally accretive in 2018. We estimate that the company’s recently-acquired Enterprise Information Systems (EIS) business is operating at a roughly $400M-$450M revenue run rate, significantly above our original estimate of $300M. We believe attrition in the EIS business may be lower than originally projected.””
A number of other equities research analysts also recently issued reports on the company. Cantor Fitzgerald restated a “buy” rating and set a $17.00 price target on shares of Allscripts Healthcare Solutions in a research note on Monday, January 8th. Citigroup began coverage on Allscripts Healthcare Solutions in a research report on Thursday, January 4th. They set a “buy” rating on the stock. BidaskClub raised Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Dougherty & Co reissued a “buy” rating and issued a $16.00 price target (up from $15.00) on shares of Allscripts Healthcare Solutions in a report on Tuesday, October 3rd. Finally, Zacks Investment Research cut Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. Allscripts Healthcare Solutions has an average rating of “Hold” and a consensus target price of $15.66.
Allscripts Healthcare Solutions (MDRX) traded up $0.15 on Tuesday, hitting $15.24. The stock had a trading volume of 1,450,735 shares, compared to its average volume of 1,861,746. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.20. The stock has a market cap of $2,750.00, a price-to-earnings ratio of -13.14, a PEG ratio of 2.16 and a beta of 1.32. Allscripts Healthcare Solutions has a 12-month low of $11.01 and a 12-month high of $16.13.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its quarterly earnings data on Thursday, November 2nd. The software maker reported $0.12 EPS for the quarter, hitting the consensus estimate of $0.12. Allscripts Healthcare Solutions had a positive return on equity of 6.53% and a negative net margin of 12.23%. equities analysts anticipate that Allscripts Healthcare Solutions will post 0.46 EPS for the current fiscal year.
In other news, SVP James Hewitt sold 36,796 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $14.11, for a total value of $519,191.56. Following the transaction, the senior vice president now directly owns 181,766 shares of the company’s stock, valued at $2,564,718.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian Farley sold 5,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $14.35, for a total value of $71,750.00. Following the completion of the transaction, the executive vice president now directly owns 191,607 shares in the company, valued at $2,749,560.45. The disclosure for this sale can be found here. Insiders have sold a total of 56,796 shares of company stock valued at $804,842 over the last 90 days. 0.75% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Archford Capital Strategies LLC grew its holdings in Allscripts Healthcare Solutions by 6,124.0% during the second quarter. Archford Capital Strategies LLC now owns 6,224 shares of the software maker’s stock worth $958,000 after acquiring an additional 6,124 shares during the period. ETF Managers Group LLC acquired a new stake in Allscripts Healthcare Solutions during the second quarter worth about $152,000. Sheaff Brock Investment Advisors LLC acquired a new stake in Allscripts Healthcare Solutions during the third quarter worth about $174,000. Crossmark Global Holdings Inc. acquired a new stake in Allscripts Healthcare Solutions during the third quarter worth about $187,000. Finally, Shelton Capital Management acquired a new stake in Allscripts Healthcare Solutions during the second quarter worth about $170,000.
COPYRIGHT VIOLATION NOTICE: This report was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://ledgergazette.com/2018/01/20/allscripts-healthcare-solutions-mdrx-earns-buy-rating-from-maxim-group.html.
Allscripts Healthcare Solutions Company Profile
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.